Look up one drug

Jardiance · DIN 02443937 Manufacturer: Boehringer-Ingelheim (Canada) Ltd./Ltee; listing date 2016-05-31 Health Canada: Marketed since 2015-08-11 · brand JARDIANCE · ATC A10BK03 EMPAGLIFLOZIN · form Tablet · route Oral · ingredients EMPAGLIFLOZIN 10 MG · company Boehringer ingelheim (canada) ltd ltee · schedule Prescription

DIN 02443937: Jardiance Raw flags: chronicUseMed=Y, insOH=Y, sec3=Y Item: 682002057; group id 743; item number 1815; lccId None; manufacturer id BOE Source form: Tab; strength: 10mg Recorded listing: General benefit; chronic-use medication (100-day supply rule, dispensing-fee limit); diabetes medication flag Source prices (unrounded): $2.8868; ministry $2.8868 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02443937 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=92871 Therapeutic Notes (formulary) Treatment of Type 2 diabetes in patients on maximally tolerated doses of metformin who have: - Inadequate glycemic control (defined as HbA1c greater than 0.07) and intolerance or contraindication to a sulfonylurea; OR - Inadequate glycemic control (HbA1c greater than 0.07) and on maximal doses of sulfonylurea and for whom insulin is not an option. Used as an adjunct to diet, exercise, and standard care therapy to reduce the incidence of cardiovascular (CV) death in patients with Type 2 diabetes and established cardiovascular disease who have inadequate glycemic control (HbA1c greater than 0.07) despite an adequate trial of metformin. Established CV disease is defined as one of the following: - history of MI - multi-vessel coronary artery disease in two or more major coronary arteries (irrespective of revascularization status) - single-vessel coronary artery disease with significant stenosis and either a positive non-invasive stress test or discharged from hospital with a documented diagnosis of unstable angina within 12 months prior to selection - last episode of unstable angina greater than 2 months prior with confirmed evidence of coronary multi-vessel or single-vessel disease - history of ischemic or hemorrhagic stroke - occlusive peripheral artery disease.

Shortage status: resolved shortage (ended 2020-09-11); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02443937

Shortage record checked 2026-09-13T08:10:21.292534+00:00

Jardiance · DIN 02443945 Manufacturer: Boehringer-Ingelheim (Canada) Ltd./Ltee; listing date 2016-05-31 Health Canada: Marketed since 2015-08-11 · brand JARDIANCE · ATC A10BK03 EMPAGLIFLOZIN · form Tablet · route Oral · ingredients EMPAGLIFLOZIN 25 MG · company Boehringer ingelheim (canada) ltd ltee · schedule Prescription

DIN 02443945: Jardiance Raw flags: chronicUseMed=Y, insOH=Y, sec3=Y Item: 682002058; group id 743; item number 1816; lccId None; manufacturer id BOE Source form: Tab; strength: 25mg Recorded listing: General benefit; chronic-use medication (100-day supply rule, dispensing-fee limit); diabetes medication flag Source prices (unrounded): $2.8868; ministry $2.8868 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02443945 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=92872 Therapeutic Notes (formulary) Treatment of Type 2 diabetes in patients on maximally tolerated doses of metformin who have: - Inadequate glycemic control (defined as HbA1c greater than 0.07) and intolerance or contraindication to a sulfonylurea; OR - Inadequate glycemic control (HbA1c greater than 0.07) and on maximal doses of sulfonylurea and for whom insulin is not an option. Used as an adjunct to diet, exercise, and standard care therapy to reduce the incidence of cardiovascular (CV) death in patients with Type 2 diabetes and established cardiovascular disease who have inadequate glycemic control (HbA1c greater than 0.07) despite an adequate trial of metformin. Established CV disease is defined as one of the following: - history of MI - multi-vessel coronary artery disease in two or more major coronary arteries (irrespective of revascularization status) - single-vessel coronary artery disease with significant stenosis and either a positive non-invasive stress test or discharged from hospital with a documented diagnosis of unstable angina within 12 months prior to selection - last episode of unstable angina greater than 2 months prior with confirmed evidence of coronary multi-vessel or single-vessel disease - history of ischemic or hemorrhagic stroke - occlusive peripheral artery disease.

Shortage status: resolved shortage (ended 2020-07-29); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02443945

Shortage record checked 2026-09-13T08:10:21.292534+00:00

Synjardy · DIN 02456575 Manufacturer: Boehringer-Ingelheim (Canada) Ltd./Ltee; listing date 2018-10-31 Health Canada: Marketed since 2016-08-03 · brand SYNJARDY · ATC A10BD20 METFORMIN AND EMPAGLIFLOZIN, A10BD20 METFORMIN AND EMPAGLIFLOZIN · form Tablet · route Oral · ingredients METFORMIN HYDROCHLORIDE 500 MG, EMPAGLIFLOZIN 5 MG · company Boehringer ingelheim (canada) ltd ltee · schedule Prescription

DIN 02456575: Synjardy Raw flags: chronicUseMed=Y, insOH=Y, sec3=Y Item: 682002066; group id 744; item number 1818; lccId None; manufacturer id BOE Source form: Tab; strength: 5mg & 500mg Recorded listing: General benefit; chronic-use medication (100-day supply rule, dispensing-fee limit); diabetes medication flag Source prices (unrounded): $1.4535; ministry $1.4535 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02456575 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=94357 Therapeutic Notes (formulary) Treatment of Type 2 diabetes in patients on maximally tolerated doses of metformin who have: - Inadequate glycemic control (defined as HbA1c greater than 0.07) and intolerance or contraindication to a sulfonylurea; OR - Inadequate glycemic control (HbA1c greater than 0.07) and on maximal doses of sulfonylurea and for whom insulin is not an option. Used as an adjunct to diet, exercise, and standard care therapy to reduce the incidence of cardiovascular (CV) death in patients with Type 2 diabetes and established cardiovascular disease who have inadequate glycemic control (HbA1c greater than 0.07) despite an adequate trial of metformin. Established CV disease is defined as one of the following: - history of MI - multi-vessel coronary artery disease in two or more major coronary arteries (irrespective of revascularization status) - single-vessel coronary artery disease with significant stenosis and either a positive non-invasive stress test or discharged from hospital with a documented diagnosis of unstable angina within 12 months prior to selection - last episode of unstable angina greater than 2 months prior with confirmed evidence of coronary multi-vessel or single-vessel disease - history of ischemic or hemorrhagic stroke - occlusive peripheral artery disease.

Shortage status: resolved shortage (ended 2022-06-20); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02456575

Shortage record checked 2026-09-13T08:10:21.292534+00:00

Synjardy · DIN 02456583 Manufacturer: Boehringer-Ingelheim (Canada) Ltd./Ltee; listing date 2018-10-31 Health Canada: Marketed since 2016-08-03 · brand SYNJARDY · ATC A10BD20 METFORMIN AND EMPAGLIFLOZIN, A10BD20 METFORMIN AND EMPAGLIFLOZIN · form Tablet · route Oral · ingredients EMPAGLIFLOZIN 5 MG, METFORMIN HYDROCHLORIDE 850 MG · company Boehringer ingelheim (canada) ltd ltee · schedule Prescription

DIN 02456583: Synjardy Raw flags: chronicUseMed=Y, insOH=Y, sec3=Y Item: 682002067; group id 744; item number 1819; lccId None; manufacturer id BOE Source form: Tab; strength: 5mg & 850mg Recorded listing: General benefit; chronic-use medication (100-day supply rule, dispensing-fee limit); diabetes medication flag Source prices (unrounded): $1.4535; ministry $1.4535 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02456583 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=94358 Therapeutic Notes (formulary) Treatment of Type 2 diabetes in patients on maximally tolerated doses of metformin who have: - Inadequate glycemic control (defined as HbA1c greater than 0.07) and intolerance or contraindication to a sulfonylurea; OR - Inadequate glycemic control (HbA1c greater than 0.07) and on maximal doses of sulfonylurea and for whom insulin is not an option. Used as an adjunct to diet, exercise, and standard care therapy to reduce the incidence of cardiovascular (CV) death in patients with Type 2 diabetes and established cardiovascular disease who have inadequate glycemic control (HbA1c greater than 0.07) despite an adequate trial of metformin. Established CV disease is defined as one of the following: - history of MI - multi-vessel coronary artery disease in two or more major coronary arteries (irrespective of revascularization status) - single-vessel coronary artery disease with significant stenosis and either a positive non-invasive stress test or discharged from hospital with a documented diagnosis of unstable angina within 12 months prior to selection - last episode of unstable angina greater than 2 months prior with confirmed evidence of coronary multi-vessel or single-vessel disease - history of ischemic or hemorrhagic stroke - occlusive peripheral artery disease.

Shortage status: no shortage or discontinuation reported (checked 2026-09-13T08:10:21.292534+00:00); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02456583

Shortage record checked 2026-09-13T08:10:21.292534+00:00

Synjardy · DIN 02456591 Manufacturer: Boehringer-Ingelheim (Canada) Ltd./Ltee; listing date 2018-10-31 Health Canada: Marketed since 2016-08-03 · brand SYNJARDY · ATC A10BD20 METFORMIN AND EMPAGLIFLOZIN, A10BD20 METFORMIN AND EMPAGLIFLOZIN · form Tablet · route Oral · ingredients METFORMIN HYDROCHLORIDE 1000 MG, EMPAGLIFLOZIN 5 MG · company Boehringer ingelheim (canada) ltd ltee · schedule Prescription

DIN 02456591: Synjardy Raw flags: chronicUseMed=Y, insOH=Y, sec3=Y Item: 682002068; group id 744; item number 1817; lccId None; manufacturer id BOE Source form: Tab; strength: 5mg & 1000mg Recorded listing: General benefit; chronic-use medication (100-day supply rule, dispensing-fee limit); diabetes medication flag Source prices (unrounded): $1.4535; ministry $1.4535 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02456591 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=94359 Therapeutic Notes (formulary) Treatment of Type 2 diabetes in patients on maximally tolerated doses of metformin who have: - Inadequate glycemic control (defined as HbA1c greater than 0.07) and intolerance or contraindication to a sulfonylurea; OR - Inadequate glycemic control (HbA1c greater than 0.07) and on maximal doses of sulfonylurea and for whom insulin is not an option. Used as an adjunct to diet, exercise, and standard care therapy to reduce the incidence of cardiovascular (CV) death in patients with Type 2 diabetes and established cardiovascular disease who have inadequate glycemic control (HbA1c greater than 0.07) despite an adequate trial of metformin. Established CV disease is defined as one of the following: - history of MI - multi-vessel coronary artery disease in two or more major coronary arteries (irrespective of revascularization status) - single-vessel coronary artery disease with significant stenosis and either a positive non-invasive stress test or discharged from hospital with a documented diagnosis of unstable angina within 12 months prior to selection - last episode of unstable angina greater than 2 months prior with confirmed evidence of coronary multi-vessel or single-vessel disease - history of ischemic or hemorrhagic stroke - occlusive peripheral artery disease.

Shortage status: no shortage or discontinuation reported (checked 2026-09-13T08:10:21.292534+00:00); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02456591

Shortage record checked 2026-09-13T08:10:21.292534+00:00

Synjardy · DIN 02456605 Manufacturer: Boehringer-Ingelheim (Canada) Ltd./Ltee; listing date 2018-10-31 Health Canada: Marketed since 2016-08-03 · brand SYNJARDY · ATC A10BD20 METFORMIN AND EMPAGLIFLOZIN, A10BD20 METFORMIN AND EMPAGLIFLOZIN · form Tablet · route Oral · ingredients EMPAGLIFLOZIN 12.5 MG, METFORMIN HYDROCHLORIDE 500 MG · company Boehringer ingelheim (canada) ltd ltee · schedule Prescription

DIN 02456605: Synjardy Raw flags: chronicUseMed=Y, insOH=Y, sec3=Y Item: 682002069; group id 744; item number 1821; lccId None; manufacturer id BOE Source form: Tab; strength: 12.5mg & 500mg Recorded listing: General benefit; chronic-use medication (100-day supply rule, dispensing-fee limit); diabetes medication flag Source prices (unrounded): $1.4535; ministry $1.4535 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02456605 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=94360 Therapeutic Notes (formulary) Treatment of Type 2 diabetes in patients on maximally tolerated doses of metformin who have: - Inadequate glycemic control (defined as HbA1c greater than 0.07) and intolerance or contraindication to a sulfonylurea; OR - Inadequate glycemic control (HbA1c greater than 0.07) and on maximal doses of sulfonylurea and for whom insulin is not an option. Used as an adjunct to diet, exercise, and standard care therapy to reduce the incidence of cardiovascular (CV) death in patients with Type 2 diabetes and established cardiovascular disease who have inadequate glycemic control (HbA1c greater than 0.07) despite an adequate trial of metformin. Established CV disease is defined as one of the following: - history of MI - multi-vessel coronary artery disease in two or more major coronary arteries (irrespective of revascularization status) - single-vessel coronary artery disease with significant stenosis and either a positive non-invasive stress test or discharged from hospital with a documented diagnosis of unstable angina within 12 months prior to selection - last episode of unstable angina greater than 2 months prior with confirmed evidence of coronary multi-vessel or single-vessel disease - history of ischemic or hemorrhagic stroke - occlusive peripheral artery disease.

Shortage status: resolved shortage (ended 2023-04-11); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02456605

Shortage record checked 2026-09-13T08:10:21.292534+00:00

Synjardy · DIN 02456613 Manufacturer: Boehringer-Ingelheim (Canada) Ltd./Ltee; listing date 2018-10-31 Health Canada: Marketed since 2016-08-03 · brand SYNJARDY · ATC A10BD20 METFORMIN AND EMPAGLIFLOZIN, A10BD20 METFORMIN AND EMPAGLIFLOZIN · form Tablet · route Oral · ingredients METFORMIN HYDROCHLORIDE 850 MG, EMPAGLIFLOZIN 12.5 MG · company Boehringer ingelheim (canada) ltd ltee · schedule Prescription

DIN 02456613: Synjardy Raw flags: chronicUseMed=Y, insOH=Y, sec3=Y Item: 682002070; group id 744; item number 1822; lccId None; manufacturer id BOE Source form: Tab; strength: 12.5mg & 850mg Recorded listing: General benefit; chronic-use medication (100-day supply rule, dispensing-fee limit); diabetes medication flag Source prices (unrounded): $1.4535; ministry $1.4535 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02456613 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=94361 Therapeutic Notes (formulary) Treatment of Type 2 diabetes in patients on maximally tolerated doses of metformin who have: - Inadequate glycemic control (defined as HbA1c greater than 0.07) and intolerance or contraindication to a sulfonylurea; OR - Inadequate glycemic control (HbA1c greater than 0.07) and on maximal doses of sulfonylurea and for whom insulin is not an option. Used as an adjunct to diet, exercise, and standard care therapy to reduce the incidence of cardiovascular (CV) death in patients with Type 2 diabetes and established cardiovascular disease who have inadequate glycemic control (HbA1c greater than 0.07) despite an adequate trial of metformin. Established CV disease is defined as one of the following: - history of MI - multi-vessel coronary artery disease in two or more major coronary arteries (irrespective of revascularization status) - single-vessel coronary artery disease with significant stenosis and either a positive non-invasive stress test or discharged from hospital with a documented diagnosis of unstable angina within 12 months prior to selection - last episode of unstable angina greater than 2 months prior with confirmed evidence of coronary multi-vessel or single-vessel disease - history of ischemic or hemorrhagic stroke - occlusive peripheral artery disease.

Shortage status: no shortage or discontinuation reported (checked 2026-09-13T08:10:21.292534+00:00); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02456613

Shortage record checked 2026-09-13T08:10:21.292534+00:00

Synjardy · DIN 02456621 Manufacturer: Boehringer-Ingelheim (Canada) Ltd./Ltee; listing date 2018-10-31 Health Canada: Marketed since 2016-08-03 · brand SYNJARDY · ATC A10BD20 METFORMIN AND EMPAGLIFLOZIN, A10BD20 METFORMIN AND EMPAGLIFLOZIN · form Tablet · route Oral · ingredients EMPAGLIFLOZIN 12.5 MG, METFORMIN HYDROCHLORIDE 1000 MG · company Boehringer ingelheim (canada) ltd ltee · schedule Prescription

DIN 02456621: Synjardy Raw flags: chronicUseMed=Y, insOH=Y, sec3=Y Item: 682002071; group id 744; item number 1820; lccId None; manufacturer id BOE Source form: Tab; strength: 12.5mg & 1000mg Recorded listing: General benefit; chronic-use medication (100-day supply rule, dispensing-fee limit); diabetes medication flag Source prices (unrounded): $1.4535; ministry $1.4535 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02456621 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=94362 Therapeutic Notes (formulary) Treatment of Type 2 diabetes in patients on maximally tolerated doses of metformin who have: - Inadequate glycemic control (defined as HbA1c greater than 0.07) and intolerance or contraindication to a sulfonylurea; OR - Inadequate glycemic control (HbA1c greater than 0.07) and on maximal doses of sulfonylurea and for whom insulin is not an option. Used as an adjunct to diet, exercise, and standard care therapy to reduce the incidence of cardiovascular (CV) death in patients with Type 2 diabetes and established cardiovascular disease who have inadequate glycemic control (HbA1c greater than 0.07) despite an adequate trial of metformin. Established CV disease is defined as one of the following: - history of MI - multi-vessel coronary artery disease in two or more major coronary arteries (irrespective of revascularization status) - single-vessel coronary artery disease with significant stenosis and either a positive non-invasive stress test or discharged from hospital with a documented diagnosis of unstable angina within 12 months prior to selection - last episode of unstable angina greater than 2 months prior with confirmed evidence of coronary multi-vessel or single-vessel disease - history of ischemic or hemorrhagic stroke - occlusive peripheral artery disease.

Shortage status: avoided shortage; reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02456621

Shortage record checked 2026-09-13T08:10:21.292534+00:00